A Phase I Dose-escalation Study of LBH589 Administered Orally in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum-tolerated dose of LBH589
1st cycle
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Japan: Ministry of Health, Labor and Welfare
CLBH589B1101
NCT00412997
November 2006
Name | Location |
---|